“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Durata Therapeutics


Durata Therapeutics products


  • Dalvance®

    • Generic Name: dalbavancin

    • Indication: intravenous treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive pathogens, including MRSA.

    • Key Feature: Long-acting lipoglycopeptide antibiotic given as two IV doses one week apart.

    • Development Notes:

      • First approved in the U.S. in May 2014.

      • High-impact designation as the first Qualified Infectious Disease Product (QIDP) under FDA’s GAIN Act.

      • Late-stage trials explored single-dose regimens and additional indications like osteomyelitis and community-acquired pneumonia.




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)